RELIBETA 30MCG/0.5ML

Indications

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Hypertension
• Heart Failure
• Cardiac Arrhythmias

Dosage

Children: Refer to the BNF for Children for appropriate dosing

Adults: Refer to the BNF for specific dosing guidelines based on the condition being treated and the formulation of the drug used.

Mechanism of action

Beta-adrenergic agonists stimulate beta-adrenergic receptors, leading to increased intracellular cAMP levels, which causes relaxation of bronchial smooth muscle and dilation of the airways. This mechanism is particularly important in the treatment of asthma and COPD, where airway constriction is a major issue. Beta-blockers, on the other hand, inhibit the effects of catecholamines on beta receptors, resulting in decreased heart rate and myocardial contractility, which is beneficial in managing hypertension and certain types of cardiac arrhythmias.

Pharmacodynamics

The pharmacodynamics of beta drugs vary depending on whether they are agonists or antagonists. Agonists lead to a dose-dependent bronchodilation and increased heart rate, while antagonists decrease heart rate and myocardial oxygen demand. The effects of these drugs can be influenced by patient-specific factors such as receptor sensitivity, presence of comorbid conditions, and concurrent medications.

Pharmacokinetics

The pharmacokinetics of beta drugs can differ substantially. Agonists are typically rapidly absorbed and distributed, with onset of action occurring within minutes. They may have short half-lives, necessitating multiple doses throughout the day. Beta-blockers, in contrast, may have longer half-lives and can be administered once or twice daily. Metabolism usually occurs in the liver, and renal excretion is common for both classes, affecting their dosing in patients with renal impairment.

Interactions

• betablockers, selective + aminophylline: Severe (increases risk of bronchospasm)
• dacomitinib + betablockers, selective: Severe (increases exposure)
• mexiletine + betablockers, selective: Severe (increases risk of cardiovascular adverse effects)
• betablockers, selective + theophylline: Severe (increases risk of bronchospasm)
• beta 2 agonists + linezolid: Severe (increases risk of elevated blood pressure)
• mao-b inhibitors + beta: Severe (increases risk of severe hypertension)
• verapamil + betablockers, non-selective: Severe (increases risk of cardiovascular adverse effects)
• cobicistat + beta: Severe (increases exposure)
• dacomitinib + betablockers, non-selective: Severe (increases exposure)
• idelalisib + beta: Severe (increases exposure)

Dosage

Children: Dosage for human-derived biological products in pediatrics should be determined based on specific product guidelines and the clinical context.

Adults: Dosage for human-derived biological products varies widely. Refer to specific product information for appropriate dosing.

Mechanism of action

Human physiology is governed by complex biological systems involving various cellular and molecular pathways. The mechanisms of action for human-derived biological products vary widely depending on the specific context, including immune response, hormonal regulation, and metabolic processes.

Pharmacodynamics

Pharmacodynamics in humans involves the interaction of drugs with biological systems, resulting in therapeutic effects. This includes receptor binding, signal transduction, and physiological responses. The effects are influenced by genetic factors, existing health conditions, and concurrent medications.

Pharmacokinetics

Pharmacokinetics in humans involves the absorption, distribution, metabolism, and excretion (ADME) of substances. Factors such as age, sex, body weight, and organ function can significantly influence these processes. Drug absorption may occur via oral, intravenous, or other routes, while distribution depends on blood flow and tissue permeability. Metabolism typically occurs in the liver, and excretion primarily takes place through the kidneys.

Pregnancy

There is no specific information available; consult local guidelines.

Breast-feeding

There is no specific information available; consult local guidelines.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Hepatitis B
• Hepatitis C
• Multiple sclerosis
• Certain types of cancer (e.g., melanoma, renal cell carcinoma)
• Condylomata acuminata (genital warts)

Dosage

Children: Refer to BNF for Children for appropriate dosing regimens based on the condition being treated.

Adults: Refer to specific product guidelines and BNF for appropriate dosing regimens based on the condition being treated.

Mechanism of action

Interferon exerts its effects by binding to specific receptors on the surface of cells, leading to the activation of intracellular signaling pathways that promote the expression of genes involved in antiviral defense, apoptosis, and immune regulation. This results in the inhibition of viral replication, enhancement of antigen presentation, and modulation of immune cell activity.

Pharmacodynamics

Interferon enhances the activity of immune cells such as natural killer cells and cytotoxic T lymphocytes. It promotes the production of various cytokines and chemokines that facilitate the immune response. Additionally, interferon has antiproliferative effects on certain tumor cells, making it useful in oncology.

Pharmacokinetics

Interferons are usually administered via subcutaneous or intramuscular injection, with peak plasma concentrations occurring approximately 3 to 8 hours after administration. They have a relatively short half-life, typically ranging from 2 to 6 hours, depending on the specific type of interferon and formulation. Interferons are metabolized primarily in the liver and excreted via the kidneys.

Contra-indications

• Severe hypersensitivity to interferon or any of its components
• Autoimmune diseases
• Severe liver disease
• Pregnancy (unless the benefit outweighs the risk)
• Severe depression or other psychiatric disorders

Adverse effects

• Flu-like symptoms (fever, chills, fatigue, headache)
• Injection site reactions (pain, redness, swelling)
• Neuropsychiatric effects (depression, anxiety, suicidal ideation)
• Hematological effects (leukopenia, thrombocytopenia)
• Liver enzyme elevation
• Thyroid dysfunction (hypothyroidism or hyperthyroidism)

Interactions

• Caution with drugs that affect the immune system
• Caution with other hepatotoxic drugs
• Potential interaction with antiepileptic medications leading to altered seizure control

Precautions

• Monitor for signs of depression or other psychiatric symptoms
• Regular monitoring of liver function tests
• Assess thyroid function prior to and during treatment
• Use caution in patients with cardiovascular disease

Pregnancy

Interferon is generally contraindicated in pregnancy due to potential risks to the fetus. It should only be used if the potential benefits justify the risks.

Breast-feeding

Caution is advised when administering interferon to breastfeeding mothers. The effects on the nursing infant are unknown.

Storage

Store in a refrigerator (2 to 8 degrees Celsius). Do not freeze. Protect from light.

Formulations

• Interferon alfa-2a
• Interferon alfa-2b
• Pegylated interferon alfa-2a
• Pegylated interferon alfa-2b

Indications

• Diabetes mellitus
• Chronic kidney disease-related anemia
• Hemophilia
• Cancer (as targeted therapy)
• Autoimmune diseases (e.g., rheumatoid arthritis)

Dosage

Children: Refer to specific product guidelines for dosing information.

Adults: Refer to specific product guidelines for dosing information.

Mechanism of action

Recombinant drugs function by mimicking the action of naturally occurring proteins in the body. For instance, recombinant insulin binds to insulin receptors on target tissues, facilitating glucose uptake and metabolism. Erythropoietin stimulates erythropoiesis by binding to erythropoietin receptors in the bone marrow, promoting the production of red blood cells.

Pharmacodynamics

The pharmacodynamics of recombinant drugs vary depending on the specific protein or hormone being replaced or supplemented. Generally, they exert their effects at the cellular level by interacting with specific receptors, leading to a cascade of biological responses. The therapeutic effects are usually dose-dependent and can vary based on the patient's biological response and the presence of antibodies against the recombinant product.

Pharmacokinetics

Pharmacokinetics of recombinant drugs include absorption, distribution, metabolism, and excretion (ADME) characteristics that can differ significantly based on the specific drug. Many recombinant proteins have a short half-life and require parenteral administration. They are typically distributed throughout the body via the bloodstream, metabolized by the liver and other tissues, and excreted primarily through the kidneys. The pharmacokinetics may be influenced by the patient's age, weight, and overall health.

Pregnancy

Recombinant proteins should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering recombinant proteins during breastfeeding, as the effects on the infant are not well established.

Storage

Store in a refrigerator at 2-8 degrees Celsius. Do not freeze, and protect from light.